Insilico Medicine

#AI / data analytics / healthtech / informatics #Drug discovery #Insilico Medicine #Servier

Partnership advances AI-driven R&D collaboration 

Insilico Medicine has achieved the early drug discovery milestone in its multi-year AI-driven drug discovery collaboration with pharmaceutical group Servier.  Under the collaboration, the two companies initiated two distinct R&D programmes for oncology on challenging targets leveraging Insilico’s proprietary end-to-end AI platform, Pharma.AI. Target nominations have been… Read More

#News

#Cellular biology #Clinical research #Drug discovery #Insilico Medicine #Virtual Aging Cell (VAC) #Virtual cell research

Insilico advances virtual cell research

Insilico Medicine has introduced biological age as a core condition in virtual cell research with the launch of its Virtual Aging Cell (VAC) Webpage and a preview of its Multi-Agent driven VAC platform. The clinical-stage drug discovery company said the platform represents the industry’s first multi-agent Virtual Aging Cell platform… Read More

#News

Automation and robotics
#Artificial intelligence (AI) #Eli Lilly #Insilico Medicine

Eli Lilly and Insilico agree AI-driven drug discovery alliance

Eli Lilly and Insilico Medicine have announced a drug discovery collaboration that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.  The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialisation of potentially best-in-class, novel oral therapeutics in… Read More

#Business & Investment #News

Tumour microenvironment
#Insilico Medicine #KRAS #Oncology #Solid tumours

Insilico Medicine nominates pan-KRAS preclinical candidate

Insilico Medicine has nominated ISM6166 as a preclinical candidate, a potent, oral pan-KRAS inhibitor designed to treat a broad spectrum of solid tumours.  Among the Ras family of oncogenes, KRAS is one of the most frequently altered drivers in human cancer, playing a key role in regulating… Read More

#Cancer Research #News

Biochemists working in the lab
#Artificial intelligence (AI) #Autoimmune disease #CNS #Collaboration #Insilico Medicine

Insilico and CMS announce CNS and autoimmune collaboration

Insilico Medicine and China Medical System (CMS) have announced a series of AI‑empowered drug discovery collaborations in the fields of central nervous system and autoimmune diseases.  According to the collaboration agreement, the parties will combine Insilico Medicine's AI-enabled drug discovery and development capabilities with CMS's experienced R&D team and disease-area… Read More

#Business & Investment #News

Node structures in the central nervous system
#Alzheimer's #Biotech #CNS #Insilico Medicine #Parkinson's

Insilico and Hygtia Therapeutics partner on CNS disease drug 

Biotechnology companies Insilico Medicine and Hygtia Therapeutics have announced a co-development collaboration agreement for Insilico’s ISM8969.  The partnership will look to accelerate the global advancement of ISM8969, an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.   The NLRP3 inflammasome is a critical component of the innate immune system but its aberrant activation is recognised… Read More

#Business & Investment #News

Stock market
#Artificial intelligence (AI) #Fundraising #Insilico Medicine #Investment #IPO

Insilico Medicine becomes 2025’s largest Hong Kong biotech IPO

Insilico Medicine listed on the Hong Kong Stock Exchange at the end of 2025, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX.   This initial public offering (IPO) raised a total of HKD 2.277 billion ($292 million), achieving the… Read More

#Business & Investment #News

Female researcher in a laboratory
#Artificial intelligence (AI) #Drug discovery #Eli Lilly #Insilico Medicine

Insilico partners with Eli Lilly on AI drug discovery 

Drug discovery company Insilico Medicine has entered a research collaboration with pharmaceutical giant Eli Lilly to advance AI-driven drug discovery.  Insilico will use its validated Pharma.AI platform to generate, design, and optimise candidate compounds against targets defined under the agreement.   The company is eligible to receive over $100 million including… Read More

#Business & Investment #News

Tumour microenvironment
#Cancer research #Drug discovery #Insilico Medicine #Solid tumours

First patient receives novel MAT2A inhibitor for solid tumours

The first patient has been dosed in a global multicentre clinical trial to evaluate ISM3412, a potentially best-in-class, MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumours. The Phase I study consists of two parts: dose escalation and dose selection optimisation, where participants will receive… Read More

#Cancer Research #News

Robot for drug discovery
#Artificial intelligence (AI) #Automation / robotics #Drug discovery #Insilico Medicine #Lab automation #Lab technology

First bipedal humanoid AI scientist joins drug discovery lab

Insilico Medicine has deployed the first bipedal humanoid in its AI-powered fully-robotic drug discovery laboratory.   The humanoid, called ‘Supervisor’, will be used for data acquisition and data generation for training of the embodied AI systems to learn the skills of human laboratory scientists.   The work… Read More

#News #Trending News

Quantum computer
#Artificial intelligence (AI) #Insilico Medicine #Oncology #Quantum computing

Quantum computing approach targets ‘undruggable’ protein

A study co-led by University of Toronto (U of T) researchers and Insilico Medicine has demonstrated the potential of quantum computing and artificial intelligence (AI) to transform the drug discovery pipeline.  “It’s an exciting time to be working at the interface of chemistry, quantum computing and AI. Read More

#Cancer Research #News #Trending News

Lungs
#Artificial intelligence (AI) #Idiopathic pulmonary fibrosis #Insilico Medicine #Lung disease #Phase II trial

Positive Phase II results for AI-created pulmonary fibrosis drug

Insilico Medicine reports improvement in patients with idiopathic pulmonary fibrosis (IPF) in a Phase IIa trial of ISM001-055. The drug, developed using generative AI, targets TNIK (Traf2- and NCK- interacting kinase) for the treatment of IPF. The topline results demonstrate that ISM001-055 is… Read More

#News

Respiratory system
#Artificial intelligence (AI) #Generative AI #Idiopathic pulmonary fibrosis #Insilico Medicine #Phase II trial

Positive Phase IIa results support AI-powered drug discovery

Insilico Medicine has shared positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055, a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase). The drug was designed utilising generative AI to treat idiopathic pulmonary fibrosis (IPF). The study met both its primary… Read More

#Editor's Choice #News

Lungs
#Artificial intelligence (AI) #Idiopathic pulmonary fibrosis #Insilico Medicine #Phase II trial

Idiopathic pulmonary fibrosis study completes enrolment

Insilico Medicine has completed patient enrolment in a Phase IIa study in China, which is investigating the safety, tolerability, and preliminary efficacy of AI-designed TNIK inhibitor INS018_055 for idiopathic pulmonary fibrosis (IPF). The randomised, double-blind, placebo-controlled study is being conducted across 29 clinical centres in China… Read More

#News

#Artificial intelligence (AI) #Generative AI #Inflammatory Bowel Disease #Insilico Medicine #Phase I trial

AI-designed PHD 1/2 inhibitor for bowel disease enters human trials

Insilico Medicine has initiated the first-in-human study for ISM5411, a poly hydroxylase domain (PHD) 1/2 inhibitor for the treatment of inflammatory bowel disease (IBD) designed by its generative AI platform. The company also plans to conduct global, multicentre Phase Ib trials in patients with ulcerative colitis… Read More

#News

Ageing hands
#Ageing #Artificial intelligence (AI) #Cancer research #Insilico Medicine #Transcriptomics #University of Chicago #University of Oslo

AI and transcriptomics identify dual targets for ageing and cancer

An international research team is the first to use artificial intelligence (AI) analysis to identify dual-purpose target candidates for the treatment of cancer and ageing. Researchers from the University of Oslo, University of Chicago Pritzker School of Medicine, and Insilico Medicine used Insilico’s AI target discovery… Read More

#Cancer Research #Editor's Choice #News